trending Market Intelligence /marketintelligence/en/news-insights/trending/oEzgCeX4SW400Ejkgc68IQ2 content esgSubNav
In This List

Lundbeck antidepressant Brintellix approved in China

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Lundbeck antidepressant Brintellix approved in China

The China Food and Drug Administration approved H. Lundbeck A/S' Brintellix for the treatment of major depressive disorder.

The company expects to launch the drug, also known as vortioxetine, in the second quarter of 2018, according to a Dec. 4 company release. It will add to Lexapro, Cipramil and Deanxit in Lundbeck's portfolio of antidepressants on the Chinese market.

Depression affects an estimated 40 million people in China, according to the release.